

## Nimodipine

Nimodipine dosing may be weight based; ensure accuracy of documented weight before administration

### CAUTION: High Administration Risk Rating

<b>Form</b>	10mg/50mL Infusion bottle	
<b>Reconstitution</b>	Already in solution	
<b>Compatibility &amp; Stability</b>	Sodium Chloride 0.9% Glucose 5% <ul style="list-style-type: none"> <li>• <b>Incompatible with PVC</b> Use polyethylene or polypropylene syringes</li> </ul>	Protect Infusion from light
<b>Administration</b>	<p><b><u>IV Continuous Infusion</u></b> Administer as a continuous IV infusion via a central catheter using an infusion pump. Connect to a three-way stopcock using the infusion line provided. The three-way stopcock should be used to connect the Nimodipine polyethylene tube with the co-infusion line and the central catheter. (The stopcock must allow for concomitant flow of the Nimodipine solution and a co-infusion solution.)</p> <p>Nimodipine solution must be administered with co-infusion running at a rate of 40 mL/hr of either sodium chloride 0.9% or glucose 5% a compatible solution in a ratio of about 1:4 (Nimodipine:co-infusion), which is connected to the second port of the threeway stopcock prior to its connection with the central line catheter. i.e. <b>For every 10mL per hour of nimodipine infused 40mL per hour of a compatible fluid must be infused simultaneously</b> to prevent formation of crystals.</p>	
<b>Monitoring</b>	<ul style="list-style-type: none"> <li>• Monitor BP and heart rate.</li> </ul>	
<b>Additional Information</b>	<ul style="list-style-type: none"> <li>• IV infusions should not be used concurrently with Nimodipine oral tablets.</li> <li>• Prepare a fresh infusion if required once 10 hours has elapsed.</li> </ul>	

**Information provided relates to Nimotop manufactured by Bayer**